Dovitinib lactate NEW
| Price | $47 | $72 | $131 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-04-27 |
Product Details
| Product Name: Dovitinib lactate | CAS No.: 692737-80-7 |
| Purity: 99.54% | Supply Ability: 10g |
| Release date: 2025/04/27 |
Product Introduction
Bioactivity
| Name | Dovitinib lactate |
| Description | Dovitinib lactate (TKI-258 lactate)(TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) (IC50 :5 nM). |
| Cell Research | Determination of cell proliferation by 3,[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) assay.?Different leukemic cells were seeded into a 96-well plate at a density of 5×10^3 cells per well and exposed to different concentrations of TKI258, with or without RAD001, in culture medium.?After incubation for indicated time points.Cell-cycle analysis:For cell-cycle analysis, cells were exposed to different concentrations of TKI258, with or without RAD001, in growth medium.?After different culture durations, cells were harvested and fixed in 70% ethanol at 4°C for over 30 min. After incubation for indicated time points, DNA contents were stained.Apoptosis analysis:Cell apoptosis was detected by determining phosphatidylserine expression on the cell surface[1]. |
| Animal Research | 21-0208 and SK-HEP1 cells as well as patient-derived HCC models were employed to study the antitumor effect of dovitinib.?Changes of biomarkers relevant to FGFR/VEGFR/PDGFR pathways were determined by Western blotting.?Microvessel density, apoptosis and cell proliferation were analyzed by immunohistochemistry[1]. |
| In vitro | ALL cells were extremely sensitive to TKI258 treatment with a concentration for 50% inhibition of cell proliferation (IC50) values in the nanomolar range in vitro.?By combination with mTOR inhibitor RAD001, a synergistic effect on cell death and cell proliferation was observed in these cells[1].Treatment of SK-HEP1 cells with dovitinib resulted in G2/M cell cycle arrest, inhibition of colony formation in soft agar and blockade of bFGF-induced cell migration. Dovitinib inhibited basal expression and FGF-induced phosphorylation of FGFR-1, FRS2-α and ERK1/2[2] |
| In vivo | In vivo, dovitinib potently inhibited tumor growth of six HCC lines.?Inhibition of angiogenesis correlated with inactivation of FGFR/PDGFR-β/VEGFR-2 signaling pathways.?Dovitinib also caused dephosphorylation of retinoblastoma, upregulation of p-histone H2A-X and p27, and downregulation of p-cdk-2 and cyclin B1, which resulted in a reduction in cellular proliferation and the induction of tumor cell apoptosis.?In an orthotopic model, dovitinib potently inhibited primary tumor growth and lung metastasis and significantly prolonged mouse survival[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 10 mg/mL (20.72 mM), Sonication is recommended. |
| Keywords | VEGFR | Vascular endothelial growth factor receptor | TKI-258 Lactate | TKI258 Lactate | TKI-258 | TKI258 | TKI 258 Lactate | TKI 258 | SCFR | Platelet-derived growth factor receptor | PDGFR | Inhibitor | inhibit | Fms like tyrosine kinase 3 | FLT3 | Fibroblast growth factor receptor | FGFR3 | FGFR | Dovitinib lactate | Dovitinib Lactate | Dovitinib | Cluster of differentiation antigen 135 | c-Kit | cKit | CHIR-258 Lactate | CHIR258 Lactate | CHIR-258 | CHIR258 | CHIR 258 Lactate | CHIR 258 | CD135 | CD117 |
| Inhibitors Related | Ribociclib | Gilteritinib | Amlexanox | Nintedanib | Regorafenib monohydrate | Sorafenib | Ferulic Acid | Regorafenib | Formononetin | Imatinib | Pazopanib | Axitinib |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Angiogenesis related Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1kg |
Nanjing Fred Technology Co., Ltd
|
2023-12-28 | ||
| $0.00/25Kg/Bag |
VIP5Y
|
Hebei Mujin Biotechnology Co.,Ltd
|
2021-04-25 | |
| $0.00/200kg |
VIP2Y
|
Qingdao RENAS Polymer Material Co., Ltd.
|
2024-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY